Blood Purification Equipment - Medical Devices Pipeline Assessment, 2017

  • ID: 4338960
  • Report
  • 160 pages
  • GlobalData
1 of 4

FEATURED COMPANIES

  • Accel Diagnostics LLC
  • Aethlon Medical Inc
  • Cerus Corp
  • CytoSorbents Corp
  • Ex Vivo Dynamics Inc
  • Immunicom Inc
  • MORE
Blood Purification Equipment - Medical Devices Pipeline Assessment, 2017

Summary

The author's Medical Devices sector report, “Blood Purification Equipment - Medical Devices Pipeline Assessment, 2017" provides an overview of Blood Purification Equipment currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Blood Purification Equipment pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by a team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope
  • Extensive coverage of the Blood Purification Equipment under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Blood Purification Equipment and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved/Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment/industry
Reasons to buy

The report enables you to:
  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Blood Purification Equipment under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Accel Diagnostics LLC
  • Aethlon Medical Inc
  • Cerus Corp
  • CytoSorbents Corp
  • Ex Vivo Dynamics Inc
  • Immunicom Inc
  • MORE
1 Table of Contents
2 Introduction
2.1 Blood Purification Equipment Overview
3 Products under Development
3.1 Blood Purification Equipment - Pipeline Products by Stage of Development
3.2 Blood Purification Equipment - Pipeline Products by Territory
3.3 Blood Purification Equipment - Pipeline Products by Regulatory Path
3.4 Blood Purification Equipment - Pipeline Products by Estimated Approval Date
3.5 Blood Purification Equipment - Ongoing Clinical Trials
4 Blood Purification Equipment - Pipeline Products under Development by Companies
4.1 Blood Purification Equipment Companies - Pipeline Products by Stage of Development
4.2 Blood Purification Equipment - Pipeline Products by Stage of Development
5 Blood Purification Equipment Companies and Product Overview
5.1 Accel Diagnostics LLC Company Overview
5.1.1 Accel Diagnostics LLC Pipeline Products & Ongoing Clinical Trials Overview
5.2 Aethlon Medical Inc Company Overview
5.2.1 Aethlon Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
5.3 Cerus Corp Company Overview
5.3.1 Cerus Corp Pipeline Products & Ongoing Clinical Trials Overview
5.4 Children's Hospital Boston Company Overview
5.4.1 Children's Hospital Boston Pipeline Products & Ongoing Clinical Trials Overview
5.5 CytoSorbents Corp Company Overview
5.5.1 CytoSorbents Corp Pipeline Products & Ongoing Clinical Trials Overview
5.6 Ex Vivo Dynamics Inc Company Overview
5.6.1 Ex Vivo Dynamics Inc Pipeline Products & Ongoing Clinical Trials Overview
5.7 Hansjorg Wyss Institute for Biologically Inspired Engineering Company Overview
5.7.1 Hansjorg Wyss Institute for Biologically Inspired Engineering Pipeline Products & Ongoing Clinical Trials Overview
5.8 Immunicom Inc Company Overview
5.8.1 Immunicom Inc Pipeline Products & Ongoing Clinical Trials Overview
5.9 McGowan Institute for Regenerative Medicine Company Overview
5.9.1 McGowan Institute for Regenerative Medicine Pipeline Products & Ongoing Clinical Trials Overview
5.10 National University of Singapore Company Overview
5.10.1 National University of Singapore Pipeline Products & Ongoing Clinical Trials Overview
5.11 NxStage Medical Inc Company Overview
5.11.1 NxStage Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
5.12 Spectral Medical Inc Company Overview
5.12.1 Spectral Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
5.13 Toray Medical Co Ltd Company Overview
5.13.1 Toray Medical Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.14 Zata Pharmaceuticals Inc Company Overview
5.14.1 Zata Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview
6 Blood Purification Equipment- Recent Developments
6.1 Jul 17, 2017: Baxter Appoints Cathy R. Smith to its Board
6.2 Jul 13, 2017: CytoSorbents Awarded $1 Million STTR Phase II Contract To Advance Development of Life-Saving Universal Plasma
6.3 Jul 09, 2017: Biocon Receives GMP approval for Biologics Drug Substance facilities from French Regulator; Drug Product facility to be re-inspected
6.4 Jul 09, 2017: Biocon: Update on Inspection Audits by French health agency
6.5 Jun 28, 2017: Aethlon Medical Announces Fiscal 2017 Results
6.6 Jun 22, 2017: Haemonetics Announces Formation of Scientific Advisory Council
6.7 Jun 14, 2017: Aethlon Medical To Present Clinical Study Results at The BIO International Convention
6.8 Jun 12, 2017: Spectral's Trial Data to Be Presented at 35th Vicenza Course on AKI and CRRT
6.9 Jun 07, 2017: Cerus Provides Update on U.S. Platelet Additive Solution Supply
6.10 Jun 05, 2017: Biocon Appoints Ms. Pratima Rao as Mission Director of Biocon Foundation
6.11 May 30, 2017: Spectral Files Final PMA Module for Toraymyxin With FDA
6.12 May 30, 2017: Dr. Eric G. Mortensen, M.D., Ph.D., Clinical Trial Veteran, Joins CytoSorbents as Chief Medical Officer
6.13 May 25, 2017: Medtronic Reports Fourth Quarter and Fiscal Year 2017 Financial Results
6.14 May 23, 2017: Cerus Provides U.S. Business Update
6.15 May 15, 2017: First Patient Transfused in Cerus’ Phase III RedeS Study Evaluating Safety and Efficacy of the INTERCEPT Red Blood Cell System
6.16 May 12, 2017: Spectral Announces First Quarter Results
6.17 May 10, 2017: Biocon statement in response to media reports on USFDA Form 483s for Biocon Limited
6.18 May 09, 2017: Cerus Announces Exercise of Additional BARDA Contract Options Totaling $46.6 million to Support INTERCEPT Red Blood Cell System Development
6.19 May 09, 2017: NxStage Reports First Quarter Financial Results
6.20 May 08, 2017: CytoSorbents Reports First Quarter 2017 Financial Results
6.21 May 08, 2017: Haemonetics Reports 4th Quarter and Fiscal Year 2017 Results and Provides Fiscal 2018 Guidance
6.22 May 05, 2017: CytoSorbents Announces Positive REFRESH I Trial Results
6.23 May 05, 2017: Biocon: Company Statement Media Reports on USFDA 483s
6.24 May 03, 2017: Cerus Reports First Quarter 2017 Results
6.25 Apr 27, 2017: Biocon Q4 FY17 Revenue Rs 974 Cr; Net Profit Rs 127 Cr; FY17 Revenue at Rs 4,079 Cr; Net Profit at Rs 612 Cr
6.26 Apr 26, 2017: Baxter Reports First-Quarter 2017 Results and Increases Financial Outlook for Full-Year 2017
6.27 Apr 24, 2017: CytoSorbents Awarded $1M Phase II SBIR Contract by U.S. Department of Defense to Advance Fungal Mycotoxin Blood Purification
6.28 Apr 24, 2017: Aethlon Medical Releases Shareholder Update
6.29 Mar 30, 2017: Spectral Announces Fourth Quarter and Fiscal 2016 Results
6.30 Mar 28, 2017: Cytosorbents Strengthens Intellectual Property Portfolio With New Patents Issued In The U.S., China, Japan, Russia, And Australia
6.31 Mar 27, 2017: CytoSorbents REFRESH I Trial Abstract Selected for Podium Presentation at the American Association for Thoracic Surgery Centennial Conference
6.32 Mar 22, 2017: Dr. Carl H. June, Cancer Immunotherapy Pioneer, Joins Cytosorbents Scientific Advisory Board
6.33 Mar 20, 2017: CytoSorb Treatment of HLH - The Parallel to Cytokine Release Syndrome in Cancer Immunotherapy
6.34 Mar 13, 2017: Aethlon Medical Announces The Conclusion Of Hemopurifier Clinical Study
6.35 Mar 08, 2017: Cytosorbents Highlights Activities At The 22nd International Conference On Advances In Critical Care Nephrology
6.36 Mar 07, 2017: U.S. FDA Approves Spectral's Third PMA Module for Its Toraymyxin Treatment of Endotoxemic Septic Shock
6.37 Mar 07, 2017: Cerus Reports Fourth Quarter and Year End 2016 Results
6.38 Mar 03, 2017: CytoSorbents Reports Record Quarterly and Full-Year 2016 Revenue
6.39 Mar 01, 2017: Aethlon Medical Announces the Grant of a European Patent Protecting Methods of Quantifying Exosomes
6.40 Feb 28, 2017: NxStage Reports Fourth Quarter and Full-Year 2016 Financial Results
6.41 Feb 23, 2017: Spectral to File Final PMA Module With the FDA for Its Toraymyxin Treatment of Endotoxemic Septic Shock
6.42 Feb 22, 2017: Aethlon Medical Reports Results of Cytomegalovirus, Epstein-Barr and Herpes Simplex Virus Studies
6.43 Feb 21, 2017: Medtronic Reports Third Quarter Financial Results
6.44 Feb 10, 2017: Aethlon Medical Announces Fiscal 2017 Third Quarter Results
6.45 Feb 08, 2017: Baxter Appoints Dr. Stephen Oesterle to Its Board
6.46 Feb 07, 2017: Cytosorbents To Present At The 19th Annual Bio CEO & Investor Conference
6.47 Feb 06, 2017: Medtronic Awarded U.S. Department of Veterans Affairs National Contracts for Home Telehealth Technologies, with Three Other Vendors
6.48 Feb 03, 2017: NxStage Announces Appointment of Chief Medical Officer
6.49 Feb 01, 2017: Baxter Reports 2016 Fourth-Quarter and Full-Year Results
6.50 Jan 31, 2017: Immunicom Provides update on TGF-beta
6.51 Jan 25, 2017: Biocon Announces Changes of Key Managerial Personnel
6.52 Jan 24, 2017: Biocon Q3 FY17 Net Profit Up 65% at Rs 171 Crore
6.53 Jan 11, 2017: Aethlon Medical Provides Clinical Study Update and a Review of 2016 Accomplishments
6.54 Jan 10, 2017: CytoSorbents Pre-announces Q4 2016 and Full-Year 2016 Results
6.55 Dec 20, 2016: CytoSorbents Announces First Sales of New CytoSorb CPB Procedure Pack for Cardiac Surgery
6.56 Dec 19, 2016: Cerus Provides an Update on the Timeline for the INTERCEPT Blood System for Red Blood Cells in Europe
6.57 Dec 19, 2016: Cerus Announces Exercise Of Additional BARDA Contract Options Totaling $10,825,555 For Activities Related To Its Planned Phase Iii Trial Of The Intercept Red Blood Cell System
6.58 Dec 15, 2016: Aethlon Announces Initiation of Sepsis-Related Virus Study
6.59 Dec 12, 2016: Cytosorbents Receives $318,551 In Non-Dilutive Funding From The New Jersey Technology Business Tax Certificate Transfer Program
6.60 Dec 12, 2016: Arteriocyte Announces Name Change to Compass Biomedical
6.61 Dec 07, 2016: CytoSorb Attains Permanent, Dedicated Reimbursement Code in Core Market of Germany
6.62 Dec 05, 2016: Spectral Medical appoints new board member
6.63 Dec 01, 2016: CytoSorb Selected for NICE MedTech Innovation Briefing in the United Kingdom
6.64 Nov 23, 2016: Golden Meditech Announces FY2016/2017 Interim Results
6.65 Nov 22, 2016: First Successful Treatment of Dengue Fever and Dengue Shock Syndrome Using CytoSorb
6.66 Nov 22, 2016: Medtronic Reports Second Quarter Financial Results
6.67 Nov 17, 2016: Cytosorbents Reports Highlights From The Sepseast 2016 Critical Care Congress
6.68 Nov 16, 2016: Medtronic Releases FY16 Integrated Performance Report
6.69 Nov 15, 2016: Adrian Thomas Joins CytoSorbents to Drive Western European Sales
6.70 Nov 11, 2016: Spectral Announces Next Steps in Path Forward and Issues Third Quarter Results
6.71 Nov 10, 2016: Aethlon Medical Announces Fiscal 2017 Second Quarter Results
6.72 Nov 07, 2016: CytoSorb Q3 2016 Sales Reach Record $2.14M, Doubling From a Year Ago
6.73 Nov 03, 2016: CytoSorbents Expands Direct Sales of CytoSorb to Belgium and Luxembourg
6.74 Nov 03, 2016: Cerus Reports Third Quarter 2016 Results
6.75 Nov 03, 2016: NxStage Reports Third Quarter Financial Results; Raises Full-Year Revenue Guidance And Cuts Net Loss Guidance In Half
6.76 Oct 27, 2016: Heartland Blood Centers Appoints Dr. Alexander Carterson As Its Medical Director
6.77 Oct 27, 2016: Catherine M. Burzik Joins Haemonetics Board of Directors
6.78 Oct 25, 2016: Baxter Reports Third Quarter 2016 Results and Increases Financial Outlook For Full-Year 2016
6.79 Oct 20, 2016: Biocon Q2 FY17 Revenue Up 21%; EBITDA Up 45%
6.80 Oct 13, 2016: Aethlon Medical Achieves DARPA Milestones, Including Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Validation
6.81 Oct 13, 2016: Cerus Announces First U.S. Blood Center Customer Submits Biologics License Application to the FDA to Allow for Interstate Export of INTERCEPT Platelet Components
6.82 Oct 11, 2016: CytoSorbents and Foxx Medical Begin Saving Lives in Chile with CytoSorb
6.83 Oct 10, 2016: Cerus Announces that Hemolife Fundación Banco Nacional de Sangre Has Entered into Routine Use of the INTERCEPT Blood System
6.84 Oct 05, 2016: CytoSorbents Announces Positive Top-line Safety Data from REFRESH I Cardiac Surgery Trial
6.85 Oct 03, 2016: Spectral Announces Clinical Trial Results
6.86 Oct 03, 2016: International Marketing of CytoSorb Commences at European Association for Cardio-Thoracic Surgery Conference
6.87 Sep 29, 2016: New Cytosorbents Website Highlights Global Growth And Innovation
6.88 Sep 23, 2016: CytoSorbents Expands CytoSorb into Iran with Partner Arsak
6.89 Sep 19, 2016: Biocon Appoints Suresh Subramanian as Head of Branded Formulations (India) Business
6.90 Sep 15, 2016: Medtronic Names Mark Ploof Senior Vice President of Global Operations and Business Services
6.91 Sep 08, 2016: CytoSorbents Advances War On Sepsis with Development of CytoSorb-XL
6.92 Aug 29, 2016: FDA's New Recommendation For Universal Zika Risk Reduction Of Blood Components Includes Use Of Pathogen Reduction
6.93 Aug 25, 2016: Medtronic Reports First Quarter Financial Results
6.94 Aug 18, 2016: Spectral on Track With Regulatory Pathway for Novel Septic Shock Treatment
6.95 Aug 12, 2016: Spectral Announces Second Quarter Results
6.96 Aug 11, 2016: Aethlon Medical Announces Zika Virus Data
6.97 Aug 11, 2016: Aethlon Medical Announces Fiscal 2017 First Quarter Results
6.98 Aug 09, 2016: Vivek Jayaraman Appointed as Cerus Corporation’s Chief Commercial Officer
6.99 Aug 09, 2016: CytoSorbents Achieves Fourth Consecutive Quarter of Record CytoSorb Sales
6.100 Aug 08, 2016: CytoSorbents Awarded $650,000 in SBIR Grant Contracts to Continue Development of Novel Hemocompatible Potassium Binding Polymers
6.101 Aug 04, 2016: NxStage Reports Second Quarter Financial Results And Raises Full-Year Revenue Guidance
6.102 Aug 04, 2016: Cerus Reports Second Quarter 2016 Results
6.103 Aug 01, 2016: Haemonetics Appoints Bill Burke CFO
6.104 Jul 26, 2016: Baxter Reports Second Quarter 2016 Results and Raises Financial Outlook for Full-Year 2016
7 Appendix
7.1 Methodology
7.2 About
7.3 Contact
7.4 Disclaimer

List of Tables
Table 1: Blood Purification Equipment - Pipeline Products by Stage of Development
Table 2: Blood Purification Equipment - Pipeline Products by Territory
Table 3: Blood Purification Equipment - Pipeline Products by Regulatory Path
Table 4: Blood Purification Equipment - Pipeline Products by Estimated Approval Date
Table 5: Blood Purification Equipment - Ongoing Clinical Trials
Table 6: Blood Purification Equipment Companies - Pipeline Products by Stage of Development
Table 7: Blood Purification Equipment - Pipeline Products by Stage of Development
Table 8: Accel Diagnostics LLC Pipeline Products & Ongoing Clinical Trials Overview
Table 9: mPharesis - Product Status
Table 10: mPharesis - Product Description
Table 11: Aethlon Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 12: ASEPSYS Device - Product Status
Table 13: ASEPSYS Device - Product Description
Table 14: Hemopurifier - Product Status
Table 15: Hemopurifier - Product Description
Table 16: Aethlon Medical Inc - Ongoing Clinical Trials Overview
Table 17: Hemopurifier - Plasma Exosome Concentration in Cancer Patients Undergoing Treatment
Table 18: Hemopurifier - Sepsis-related Virus Study of Aethlon Hemopurifier
Table 19: Cerus Corp Pipeline Products & Ongoing Clinical Trials Overview
Table 20: INTERCEPT Blood System - Chikungunya Virus - Product Status
Table 21: INTERCEPT Blood System - Chikungunya Virus - Product Description
Table 22: INTERCEPT Blood System - Dengue Virus - Product Status
Table 23: INTERCEPT Blood System - Dengue Virus - Product Description
Table 24: INTERCEPT Blood System - Platelets - Product Status
Table 25: INTERCEPT Blood System - Platelets - Product Description
Table 26: INTERCEPT Blood System - Red Blood Cells - Product Status
Table 27: INTERCEPT Blood System - Red Blood Cells - Product Description
Table 28: INTERCEPT Blood System - Zika Virus - Product Status
Table 29: INTERCEPT Blood System - Zika Virus - Product Description
Table 30: Cerus Corp - Ongoing Clinical Trials Overview
Table 31: INTERCEPT Blood System - Red Blood Cells - A Randomized Controlled Study to Evaluate Efficacy and Safety of S 303 Treated Red Blood Cells (RBC) in Subjects with Thalassemia Major Requiring Chronic RBC Transfusion
Table 32: INTERCEPT Blood System - Zika Virus - A Randomized, Double-blind, Controlled, Parallel Group Study with the INTERCEPT Blood System for Red Blood Cells in Regions at Potential Risk for Zika Virus Transfusion-transmitted Infections (RedeS Study) and Treatment Use Open-label Extension Study
Table 33: Children's Hospital Boston Pipeline Products & Ongoing Clinical Trials Overview
Table 34: Micromagnetic-Microfluidic Device - Product Status
Table 35: Micromagnetic-Microfluidic Device - Product Description
Table 36: Surface-Modified Circuit - Product Status
Table 37: Surface-Modified Circuit - Product Description
Table 38: CytoSorbents Corp Pipeline Products & Ongoing Clinical Trials Overview
Table 39: BetaSorb - Product Status
Table 40: BetaSorb - Product Description
Table 41: ContrastSorb - Product Status
Table 42: ContrastSorb - Product Description
Table 43: CST 301 - Product Status
Table 44: CST 301 - Product Description
Table 45: CytoSorb - Product Status
Table 46: CytoSorb - Product Description
Table 47: CytoSorb - Cytokine Release Syndrome - Product Status
Table 48: CytoSorb - Cytokine Release Syndrome - Product Description
Table 49: CytoSorb-XL - Product Status
Table 50: CytoSorb-XL - Product Description
Table 51: DrugSorb - Product Status
Table 52: DrugSorb - Product Description
Table 53: HemoDefend - Product Status
Table 54: HemoDefend - Product Description
Table 55: CytoSorbents Corp - Ongoing Clinical Trials Overview
Table 56: CytoSorb - Case-observation and Compassionate Use: Use of Extracorporeal Treatment with the Cytosorb-Adsorber for the Reduction of Postoperative Hyperinflammation and SIRS After Heart-surgery with the Use of a Heart-lung-machine
Table 57: CytoSorb - Cytokine Adsorption in Sepsis and Acute Kidney Injury
Table 58: CytoSorb - Cytokine Clearance with Cytoabsorbant Device During Cardiac Bypass: A Pilot Study
Table 59: CytoSorb - Elimination of Antibiotics During Combined Continuous Renal Replacement Therapy and Cytosorb Adsorptive Therapy in Patients with Sepsis and Acute Kidney Injury
Table 60: CytoSorb - Extracorporeal Elimination of Cytokines Following Abdominal-thoracic Esophagectomy - A Randomized Study : EXCESS
Table 61: CytoSorb - Extracorporeal Therapy for the Removal of Myoglobin Using the CytoSorb in Patients with Rhabdomyolysis
Table 62: CytoSorb - Immunomodulatory Effect of Extracorporeal Cytokine Adsorption in Cardiac Surgery
Table 63: CytoSorb - International Registry on the Use of the CytoSorb-Adsorber in ICU Patients
Table 64: CytoSorb - Myeloid-derived Supressor Cells in Uncomplicated Versus Complicated Patients after Cardiac Surgery
Table 65: CytoSorb - Pancreatitis CytoSorbents (CytoSorb) Inflammatory Cytokine Removal: A Prospective Study
Table 66: CytoSorb - Reduction of Inflammation Reaction to Extracorporeal Circulation in Cardiac Surgery by Interleukin Dialysis
Table 67: CytoSorb - Removal of Cytokine on Cardiopulmonary Bypass with CytoSorb Compared to on- and Off-pump Myocardial Revascularization
Table 68: CytoSorb - Removal of Cytokines During Cardiac Surgery
Table 69: CytoSorb - Removal of Cytokines in Patients Undergoing Cardiac Surgery with CPB (The REMOTE Study)
Table 70: CytoSorb - The Effect of Early Cytokine Absorption on the Systemic Inflammatory Response Syndrome and Organ Dysfunction in the First 48 Hours of Septic Shock
Table 71: CytoSorb - The Impact of Pre-emptive Intraoperative Use of Extracorporeal Cytokine Adsorption during Orthotopic Heart Transplantation
Table 72: Ex Vivo Dynamics Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 73: Blood Filter Device - Product Status
Table 74: Blood Filter Device - Product Description
Table 75: Hansjorg Wyss Institute for Biologically Inspired Engineering Pipeline Products & Ongoing Clinical Trials Overview
Table 76: Sepsis Therapeutic Device - Improved Version - Product Status
Table 77: Sepsis Therapeutic Device - Improved Version - Product Description
Table 78: Spleen-On-A-Chip - Product Status
Table 79: Spleen-On-A-Chip - Product Description
Table 80: Immunicom Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 81: Immunopheresis Blood-Filtering Device - Product Status
Table 82: Immunopheresis Blood-Filtering Device - Product Description
Table 83: McGowan Institute for Regenerative Medicine Pipeline Products & Ongoing Clinical Trials Overview
Table 84: Hemoadsorption Device - Sepsis - Product Status
Table 85: Hemoadsorption Device - Sepsis - Product Description
Table 86: National University of Singapore Pipeline Products & Ongoing Clinical Trials Overview
Table 87: Microfluidic Device - Sepsis - Product Status
Table 88: Microfluidic Device - Sepsis - Product Description
Table 89: NxStage Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 90: DLT Device - Sepsis - Product Status
Table 91: DLT Device - Sepsis - Product Description
Table 92: Spectral Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 93: Toraymyxin PMX-20R - Product Status
Table 94: Toraymyxin PMX-20R - Product Description
Table 95: Spectral Medical Inc - Ongoing Clinical Trials Overview
Table 96: Toraymyxin PMX-20R - Efficacy of Polymyxin B Hemoperfusion on Severe Sepsis Secondary to Pneumonia or Urinary Tract Infection: A Single-arm Clinical Trial
Table 97: Toraymyxin PMX-20R - Evaluating the Use of Polymyxin B Hemoperfusion in a Prospective Non-controlled Trial in Adults
Table 98: Toraymyxin PMX-20R - The Effect of Endotoxin Adsorber Hemoperfusion on the Microcirculation in Patients with Severe Sepsis and Septic Shock
Table 99: Toray Medical Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 100: Toray Leukocyte Removal Column - Product Status
Table 101: Toray Leukocyte Removal Column - Product Description
Table 102: Zata Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 103: Anti - Pathogen Device - Product Status
Table 104: Anti - Pathogen Device - Product Description
Table 105: Glossary

List of Figures
Figure 1: Blood Purification Equipment - Pipeline Products by Stage of Development
Figure 2: Blood Purification Equipment - Pipeline Products by Territory
Figure 3: Blood Purification Equipment - Pipeline Products by Regulatory Path
Figure 4: Blood Purification Equipment - Pipeline Products by Estimated Approval Date
Figure 5: Blood Purification Equipment - Ongoing Clinical Trials
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Accel Diagnostics LLC
  • Aethlon Medical Inc
  • Cerus Corp
  • Children's Hospital Boston
  • CytoSorbents Corp
  • Ex Vivo Dynamics Inc
  • Hansjorg Wyss Institute for Biologically Inspired Engineering
  • Immunicom Inc
  • McGowan Institute for Regenerative Medicine
  • National University of Singapore
  • NxStage Medical Inc
  • Spectral Medical Inc
  • Toray Medical Co Ltd
  • Zata Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll